Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Upcoming SlideShare
Outthinker 45 Min Talk for Columbia Alumni Club NY
Next
Download to read offline and view in fullscreen.

0

Share

TapImmune, Inc. (OTCBB: TPIV; Stock Twits: $TPIV)

Download to read offline

TapImmune Inc. (OTCBB: TPIV) is a biotechnology company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and infectious disease. The company's lead product, the TAP vaccine performs a key step in moving characteristic markers called antigens to the surfaces of cells.

Related Books

Free with a 30 day trial from Scribd

See all

Related Audiobooks

Free with a 30 day trial from Scribd

See all
  • Be the first to like this

TapImmune, Inc. (OTCBB: TPIV; Stock Twits: $TPIV)

  1. 1. 08/01/11 TapImmune Inc OTC BB:TPIV www.tapimmune.com OTCBB: TPIV
  2. 2. Cautionary Statement Regarding Forward Looking Statements <ul><li>Certain statements contained herein are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this document include, but are not limited to, statements relating to long-term stability, the Company ’s plan of operations and finances, the potential for the Company’s vaccines and proposed clinical trials. </li></ul><ul><li>The reader is cautioned that any such forward-looking statements are not guarantees of future performance and that actual results may differ materially from estimates in the forward-looking statements. The Company undertakes no obligation to revise these forward-looking statements to reflect events or circumstances after the date hereof. </li></ul>08/01/11 TapImmune Inc
  3. 3. 08/01/11 TapImmune Inc “ Development of Immunotherapies for cancer & infectious disease ”
  4. 4. Market for Immunotherapies/Vaccines <ul><li>Fastest growing segment of pharmaceutical market: </li></ul><ul><ul><li>Cancer: </li></ul></ul><ul><ul><ul><li>Projected $6 billion U.S. for cancer vaccines by 2010 with CAGR of 70-100% </li></ul></ul></ul><ul><ul><ul><li>Stimulated by recent approvals of Dendreon ’s Provenge and BMS Yervoy </li></ul></ul></ul><ul><ul><li>Infectious Disease: </li></ul></ul><ul><ul><ul><li>Projected market for 2010 - $11 billion </li></ul></ul></ul><ul><ul><ul><li>Viral pandemics, societal pathogens, bio-defense </li></ul></ul></ul>08/01/11 TapImmune Inc
  5. 5. TAP Technology Platform <ul><li>TAP – Transporters associated with antigen presentation </li></ul><ul><li>Key component in immune recognition pathway </li></ul><ul><li>Stimulates T-cell recognition of antigens and production of cytotoxic T-cells that can infiltrate tumors </li></ul><ul><li>Patents confer broad IP protection </li></ul>08/01/11 TapImmune Inc
  6. 6. TAP is “switched off” in Cancer <ul><li>Many tumors have low or no expression of TAP </li></ul><ul><li>Tumors not recognized as foreign by immune system </li></ul><ul><li>Diminished expression of TAP is associated with disease susceptibility, progression and metastasis </li></ul><ul><li>Vectors re-introducing TAP into tumors boost immunity and reduce tumor burden </li></ul>08/01/11 TapImmune Inc
  7. 7. Need to Augment TAP levels in Infectious Disease <ul><li>Viral infections produce a range of viral peptides that may “overwhelm” TAP system </li></ul><ul><li>Insufficient viral antigens presented to the cellular immune system </li></ul><ul><li>Diminished expression of TAP is associated with disease susceptibility </li></ul><ul><li>Vectors augmenting normal TAP levels boost immunity and greatly improved vaccine efficacy </li></ul>08/01/11 TapImmune Inc
  8. 8. Role of TAP (TAP1/TAP2) in loading peptides to MHC Class I molecules and presentation to Cytotoxic T-cells 08/01/11 TapImmune Inc
  9. 9. 08/01/11 TapImmune Inc TAP treatment restores Immune Recognition in Cancer Tumor cells now visible to the immune system TAP
  10. 10. 08/01/11 TapImmune Inc TAP Enhances Immune Recognition in Infectious Disease Greater number of viral antigens visible to the immune system TAP
  11. 11. Efficacy of TAP vector technology <ul><li>Cancer: </li></ul><ul><ul><li>Mouse models of metastatic melanoma and small cell lung cancer: </li></ul></ul><ul><ul><ul><li>Reduced metastasis </li></ul></ul></ul><ul><ul><ul><li>Higher survival </li></ul></ul></ul><ul><li>Infectious Disease: </li></ul><ul><ul><li>100-1000 fold increase in efficacy of smallpox vaccine in animals. </li></ul></ul>08/01/11 TapImmune Inc
  12. 12. Clinical Development: HER2/neu +ve Breast Cancer Vaccine <ul><li>Combination of TAP + HER2/neu antigens from Mayo Clinic </li></ul><ul><ul><li>applicable to ~ 80% of HER2/neu +ve patients </li></ul></ul><ul><ul><li>IND for Phase I studies approved </li></ul></ul><ul><li>Current therapy: </li></ul><ul><ul><li>Trastuzumab (Herceptin) over $5billion in annual sales </li></ul></ul><ul><ul><li>applicable to ~ 30% of HER2/neu +ve patients </li></ul></ul>08/01/11 TapImmune Inc
  13. 13. Research Smallpox/Biodefense Vaccines <ul><li>TAP improved potency of smallpox vaccine by 100-1000 fold </li></ul><ul><li>TAP + peptide antigens licensed from Mayo Clinic </li></ul><ul><ul><li>Broader patient population; cheaper, longer shelf-life </li></ul></ul><ul><li>“ Animal Efficacy Rule” FDA pathway (24-36 months to potential stockpiling) </li></ul><ul><li>Potential for TAP to be stockpiled for variety of emerging bio-threats, e.g. Dengue </li></ul>08/01/11 TapImmune Inc
  14. 14. Leverage of Collaborations <ul><li>Crucell NV </li></ul><ul><ul><li>TAP manufacturing </li></ul></ul><ul><li>Research Collaboration with Aeras Global TB Vaccine Foundation </li></ul><ul><ul><li>TB antigens (Phase II clinical) + TAP </li></ul></ul><ul><li>License Option Agreements with Mayo Clinic: </li></ul><ul><ul><li>HER2/neu +ve breast cancer antigen technology </li></ul></ul><ul><ul><li>Smallpox virus antigen technology </li></ul></ul>08/01/11 TapImmune Inc
  15. 15. Advisors & R&D Team <ul><ul><li>Mac Cheever (Corixa; Fred Hutchinson Cancer Center) </li></ul></ul><ul><ul><li>Mark Reddish (Biomira; ID Biomedical) </li></ul></ul><ul><ul><li>Keith Knutson (Mayo Clinic) </li></ul></ul><ul><ul><li>Greg Poland (Mayo Clinic) </li></ul></ul><ul><ul><li>Lynn Depippo (Sherbrook Capital Management) </li></ul></ul>08/01/11 TapImmune Inc
  16. 16. 08/01/11 TapImmune Inc <ul><li>Technology discovery at University of British Columbia </li></ul><ul><li>Founded as a public corporation on OTCBB (TPIV) </li></ul><ul><li>Based in Seattle, WA </li></ul><ul><li>~ 47 million shares outstanding (22 million in float) </li></ul><ul><li>Management & Affiliates ~ 30% </li></ul>Corporate Profile www.tapimmune.com
  17. 17. Our Vision for TAP <ul><li>Leading immunotherapy in the fight against cancer: </li></ul><ul><ul><li>Multiple metastatic cancers </li></ul></ul><ul><ul><li>Multiple combination products </li></ul></ul><ul><ul><li>Early stage prophylactic use </li></ul></ul><ul><li>Stockpiled for biodefense threats and viral pandemics: </li></ul><ul><ul><li>Variety of infectious diseases </li></ul></ul><ul><ul><li>Emerging bio-terrorist threats </li></ul></ul><ul><ul><li>Making other vaccines more effective </li></ul></ul>08/01/11 TapImmune Inc
  18. 18. Looking for Investors that Share our Vision Why Invest in TPIV now? <ul><li>Breakthrough technology </li></ul><ul><li>Strong product pipeline </li></ul><ul><li>World-class team and collaborators </li></ul><ul><li>Risk diversification – cancer & infectious disease </li></ul><ul><li>Compelling preclinical data </li></ul><ul><li>Start of clinical programs </li></ul><ul><li>Undervalued and poised for significant growth </li></ul>08/01/11 TapImmune Inc

TapImmune Inc. (OTCBB: TPIV) is a biotechnology company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and infectious disease. The company's lead product, the TAP vaccine performs a key step in moving characteristic markers called antigens to the surfaces of cells.

Views

Total views

1,495

On Slideshare

0

From embeds

0

Number of embeds

84

Actions

Downloads

6

Shares

0

Comments

0

Likes

0

×